Logo

Asterand to Use Rubicon s Whole-Genome Amplification Technology for Diabetes Research

May 26, 2004

NEW YORK, May 26 (GenomeWeb News) - Tissue-banking firm Asterand will use DNA amplification technology developed by Rubicon Genomics as part of a collaborative diabetes study, Asterand said today.

 

Asterand said it will use Rubicon's GenomePlex whole-genome amplification technology to obtain DNA samples from relatives of diabetes patients in a collaborative study that involves researchers from WayneStateUniversity and elsewhere.

 

The trial will collect blood samples from people suffering from diabetes, but other family members "may prefer a simple mouthwash, and by using this new amplification technology we can get the information we need," said Asterand CSO James Eliason.

 

Asterand said it will begin using the amplification method in Europe this month.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.